Article By:
Don Dion
Friday, November 25, 2016 10:33 AM EDT
While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio.